Combination of gemcitabine-containing magnetoliposome and oxaliplatin-containing magnetoliposome in breast cancer treatment: A possible mechanism with potential for clinical application.
Breast cancer is a major global health problem with high incidence and case fatality rates. The use of magnetoliposomes has been suggested as an effective therapeutic approach because of their good specificity for cancers. In this study, we developed two novel magnetoliposomes, namely, Gemcitabine-containing magnetoliposome (GML) and Oxaliplatin-containing magnetoliposome (OML). These magnetoliposomes were combined (CGOML) was used to treat breast cancer under an external magnetic field. Biosafety test results showed that GML and OML were biologically safe to blood cells and did not adversely affect the behavior of mice. Pharmacokinetic and tissue distribution studies indicated that both magnetoliposomes exhibited stable structures and persisted at the target area under an external magnetic field. Cell and animal experiments revealed that CGOML can markedly suppress the growth of MCF-7 cells, and only the CGOML group can minimize the tumor size among all the groups. Finally, CGOML can significantly inhibit MCF-7cell growth both in vitro and vivo by activating the apoptotic signaling pathway of MCF-7 cells.
['Ye|Hui|H|', 'Tong|Jiansong|J|', 'Liu|Jiangyi|J|', 'Lin|Wenman|W|', 'Zhang|Chengshou|C|', 'Chen|Kai|K|', 'Zhao|Jie|J|', 'Zhu|Wenjing|W|']
D000818:Animals D000971:Antineoplastic Combined Chemotherapy Protocols D001943:Breast Neoplasms D003841:Deoxycytidine D016503:Drug Delivery Systems D005260:Female D006801:Humans D008081:Liposomes D058185:Magnetite Nanoparticles D051379:Mice D008819:Mice, Nude D009944:Organoplatinum Compounds D000077150:Oxaliplatin D023041:Xenograft Model Antitumor Assays
magnetoliposome breast cancer MCF-7 gemcitabine oxaliplatin